INTRODUCTION: Pressure ulcers (PU) are one of the main challenges for nursing in our country. Wound bed preparation and the TIME algorithm provide essential tools for adequately treating these lesions. However, these wounds tend to become chronic due to the bacterial load in their bed. It is now known that bacteria can form complex and diverse structures, named as biofilm, which are difficult to diagnose and much more resistant to antimicrobial action.
Controlling these biofilms is crucial to create the optimal conditions for wound healing. Currently, it is believed that biofilms are present in 60-100% of chronic wounds. Therefore, more studies are needed to evaluate the efficacy of different antimicrobial agents on these structures.
OBJECTIVE: To determine the efficacy of a gel containing polyhexanide and biguanide, alone or in combination with alginate with or without silver, in preventing biofilm in PU, in terms of healing at 4 weeks.
METHODOLOGY: Multicenter clinical trial with a 2x2 factorial design, conducted with patients from Alcoy with category II and III PUs that meet the inclusion and exclusion criteria. A sample of 140 participants is estimated, distributed into four groups of 35 patients. The interventions that will be carried out will be: application of Prontosan gel® and Aquacel Ag+®; Aquacel Ag+®; control group; Prontosan gel®. Data on wound evolution will be collected using RESVECH 2.0. Descriptive statistical analysis and hypothesis testing will be performed.

开始日期2026-01-30

申办/合作机构-

IRCT20190210042676N49

/ Recruiting临床2期

Evaluation of effectiveness and safety of antibacterial dressing containing polyhexamethylene biguanide in treatment of chronic wounds

开始日期2025-12-21

申办/合作机构-

NCT07195864

/ CompletedN/A

Retrospective Chart Review of Patients With Acanthamoeba Keratitis Who Have Received 0.8 mg/mL Polihexanide as Part of the "Medicines in Special Situations" (Medicamentos en Situaciones Especiales) Program in Spain.

The study will be a multicentric, retrospective, non-interventional medical chart review of patients with AK who initiated a treatment with 0.8 mg/ml polihexanide as part of the Spanish Medicines in Special Situations program, whether they fully completed the treatment or not.
Baseline date is defined as the date of 0.8 mg/ml polihexanide initiation. The Study Period for each patient will be considered the period from the baseline to the conclusion of the treatment.

开始日期2025-10-30

申办/合作机构

SIFI SpA

100 项与聚己缩胍相关的临床结果

登录后查看更多信息

100 项与聚己缩胍相关的转化医学

登录后查看更多信息

100 项与聚己缩胍相关的专利（医药）

登录后查看更多信息

795

项与聚己缩胍相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Effects of extended-release topical polyhexanide in a Staphylococcus aureus–induced murine dermatitis model characterized by IL-36 expression

Article

作者: Bresnick, Stephen ; Burnam, Bradley

OBJECTIVES:

Atopic dermatitis is a chronic inflammatory skin disorder characterized by epidermal barrier dysfunction, microbial dysbiosis, and dysregulated immune signaling. Staphylococcus aureus colonization is associated with disease severity and contributes to inflammatory amplification, with IL-36 serving as a marker of epithelial stress. Polyhexanide is a cationic polymer delivered in topical formulations. GX03 is a novel extended-release topical formulation designed to provide sustained delivery of liquid polyhexanide at the skin surface. This study evaluated whether GX03 reduces disease severity in a murine model of S. aureus-induced cutaneous inflammation characterized by IL-36 expression.

METHODS:

Skin inflammation was induced using a standardized S. aureus exposure protocol, with confirmation of IL-36 protein expression. Animals were treated topically with GX03 or left untreated. Disease severity was assessed with blinded investigator global assessment scoring using the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD).

RESULTS:

Epicutaneous S. aureus exposure produced reproducible inflammatory disease with consistent IL-36 expression. Treatment with GX03 resulted in a significant reduction in disease severity, with mean global assessment scores decreasing from 3.00 in untreated controls to 1.44 in treated animals (52% reduction; p = 0.0003).

CONCLUSIONS:

These findings suggest that extended-release topical polyhexanide (GX03) reduces disease severity in a murine dermatitis model characterized by IL-36 expression.

2026-12-01·PARASITOLOGY RESEARCH

Multidrug-resistant Acanthamoeba keratitis caused by the T4 Genotype: A case report

Article

作者: Kazemirad, Elham ; Atighehchian, Mehrnaz ; Zarei-Ghanavati, Mehran ; Kasiri, Maryam ; Latifi, Alireza

This report describes the case of a 28-year-old woman, who presented with a two-week history of severe ocular pain and photophobia in her right eye. She was a soft contact lens wearer with no history of ocular trauma or systemic illness. Ophthalmic examination revealed conjunctival hyperemia, epithelial irregularities, and a developing ring-shaped stromal infiltrate. In vivo confocal microscopy demonstrated double-walled hyperreflective cysts, and culture followed by PCR and sequencing confirmed the presence of Acanthamoeba T4 genotype. Despite intensive treatment with topical polyhexamethylene biguanide, chlorhexidine, propamidine, and voriconazole, as well as oral miltefosine, the infection progressed, leading to stromal necrosis. The patient underwent two therapeutic penetrating keratoplasties; however, the disease continued to advance, eventually resulting in phthisis bulbi and permanent vision loss. This case highlights the potential for aggressive, clinically refractory Acanthamoeba keratitis caused by the T4 genotype, emphasizing the importance of early diagnosis, vigilant monitoring, and timely surgical intervention in resistant cases.

2026-09-01·JOURNAL OF DENTISTRY

Antiseptic mouthwashes as a potential strategy for controlling oral dysbiosis: Antimicrobial effect against opportunistic pathogens

Article

作者: Cielecka-Piontek, Judyta ; Paczkowska-Walendowska, Magdalena ; Karpiński, Tomasz M ; Korbecka-Paczkowska, Marzena

OBJECTIVES:

Oral dysbiosis is increasingly recognized as a clinically relevant condition associated with oral diseases, systemic complications, and the emergence of antimicrobial-resistant microorganisms. Antiseptic-containing mouthwashes are widely used as adjunctive, non-antibiotic tools in oral hygiene; however, comparative data on their activity against dysbiosis-associated microorganisms and their clinical efficiency at formulation-relevant concentrations remain limited.

METHODS:

In this study, the antimicrobial activity of commercially available mouthwashes containing octenidine dihydrochloride (OCT), chlorhexidine digluconate (CHX), polyhexamethylene biguanide (PHMB), and cetylpyridinium chloride (CPC) was evaluated against Gram-positive and Gram-negative bacteria and Candida spp. associated with oral dysbiosis. Minimum inhibitory concentrations (MICs) were determined by broth microdilution and expressed both as product dilutions and active compound concentrations. Clinical relevance was assessed using the Clinical Efficiency of MIC (CEMIC) index.

RESULTS:

OCT-containing mouthwashes demonstrated the lowest MIC and CEMIC values and the most consistent antimicrobial activity against all tested microorganisms. CHX-based formulations showed high activity against Gram-positive bacteria and Candida spp. but were markedly less effective against Gram-negative pathogens. PHMB exhibited lower antimicrobial potency; however, its CEMIC values indicated clinical efficiency at formulation-relevant concentrations.

CONCLUSIONS:

The results demonstrate in vitro antimicrobial activity of antiseptic mouthwashes against microorganisms associated with oral dysbiosis and suggest that they may have potential as non-antibiotic adjuncts, although this requires clinical validation.

CLINICAL SIGNIFICANCE:

This study demonstrates that antiseptic mouthwashes, particularly those containing octenidine, chlorhexidine and polyhexanide, effectively control oral dysbiosis at commercial concentrations. By using the CEMIC index, our findings provide evidence-based guidance for non-antibiotic oral care, reduce antimicrobial resistance risk, and support improved oral health.

项与聚己缩胍相关的新闻（医药）

2026-08-20

·BioSpace

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7% Findings support Turn’s approach of acting earlier in the inflammatory process, before inflammation becomes fully established WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease. The study, published in Life , showed that pretreatment with GX-03 reduced IL-36α and IL-36γ release by approximately 50%. IL-36 is an important early signal in the inflammatory cascade and helps amplify inflammation in the skin. GX-03 also reduced IL-31 by nearly 68%. IL-31 is closely associated with itch in inflammatory skin diseases such as atopic dermatitis. In addition, IL-4, another important inflammatory cytokine involved in the immune response, was reduced by 16.7%. Importantly, IL-13 was essentially unchanged, suggesting that GX-03 did not suppress every inflammatory signal measured, but instead produced a selective pattern of cytokine reduction. These biological changes were accompanied by a 66% reduction in clinical dermatitis severity in GX-03-pretreated animals compared with untreated controls. “This publication provides important new biological evidence about GX-03,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “In-vivo, GX-03 strongly reduced IL-36, a key early driver of the inflammatory cascade, as well as IL-31, a major driver of itch. It also reduced IL-4, an important inflammatory signal. What is particularly interesting is when this occurred. Rather than targeting inflammation only after it is already established, GX-03 was present before the challenge and substantially reduced the inflammatory response that followed skin challenge. We believe this supports a fundamentally different approach: modifying the local skin environment upstream, before the inflammatory cascade takes hold.” The timing of the intervention is an important part of the study. Many current therapies for atopic dermatitis are designed to block inflammatory pathways after disease and inflammation are already established. In this study, researchers applied GX-03 before exposing the skin to a standardized bacterial challenge known to trigger atopic dermatitis-like inflammation. They then measured the inflammatory response that developed afterward. Animals pretreated with GX-03 developed substantially less severe dermatitis and showed significant reductions in IL-36α, IL-36γ, IL-31 and IL-4. The study therefore provides a different experimental perspective on inflammatory skin disease by examining whether modifying the skin environment can change the intensity and pattern of the inflammatory response. The study evaluated 40 mice that received either no pretreatment or four days of topical GX-03 before standardized Staphylococcus aureus exposure. Following predefined exclusions, 18 animals in each group were included in the final analysis. GX-03 pretreatment reduced mean clinical disease severity from a vIGA-AD score of 2.44 in untreated animals to 0.83, representing a 66.0% reduction. IL-36α expression decreased by 49.9%, IL-36γ by 50.9%, IL-31 by 67.7%, and IL-4 by 16.7%. IL-13 did not differ significantly between the groups. No local irritation, dryness, redness, barrier disruption or other adverse skin findings were observed during the GX-03 pretreatment period. The publication, titled “Effects of Extended-Release Polyhexanide on Inflammatory Cytokine Expression and Disease Severity Following Staphylococcus aureus Exposure in a Murine Dermatitis Model,” was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen D. Bresnick, M.D., an independent researcher. The study was conducted at Altogen Labs under an IACUC-approved protocol and builds upon Turn Therapeutics’ previously published research in the Journal of Dermatological Treatment . About GX-03 GX-03 is Turn Therapeutics’ proprietary, non-systemic topical investigational therapy currently in clinical development for atopic dermatitis. GX-03 is designed to act locally in the skin, where Turn is investigating whether modifying the local skin environment can reduce important inflammatory signals associated with disease while avoiding broad systemic immune suppression. The newly published findings provide in-vivo evidence that GX-03 is associated with selective reductions in IL-36, IL-31 and IL-4 following a standardized skin challenge. GX-03 is currently being evaluated in a randomized, double-blind, vehicle-controlled clinical trial in atopic dermatitis. About Turn Therapeutics Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics’ lead investigational topical candidate and is being developed as a targeted, non-systemic treatment for atopic dermatitis. Citation Burnam B, Bresnick S. Effects of Extended-Release Polyhexanide on Inflammatory Cytokine Expression and Disease Severity Following Staphylococcus aureus Exposure in a Murine Dermatitis Model. Life . 2026. DOI: 10.3390/life16081369 Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise. Contacts Turn Therapeutics Investor & Media Contact Sasha Damouni The Damouni Group Sasha@turntherapeutics.com

临床结果

2026-07-20

·VIVworldwide

VIV SELECT CHINA 2026 亚洲国际集约化畜牧展览会（上海） 8月19-21日丨上海世博展览馆做外贸生意来VIV，让订单源源不断共赴 VIV SELECT CHINA 2026展会之约！精准获客，高效成交，直面决策者持续为您提升品牌声量展位火爆销售中参展锁定外贸商机增长动能 8月相聚上海！展商推荐天津中升挑战生物科技有限公司 Tianjin Speerise Challenge Biotechnology CO., LTD. 2号馆 H2D2311 展位号 2026/8/19-21 相约上海欢迎新老朋友前来洽谈合作 01 FIRST 公司简介天津市中升挑战生物科技有限公司（简称：挑战动保）成立于2002年，公司专注于动物保健领域，聚焦食品及伴侣动物健康。挑战动保以创新驱动发展，构建药物研发、生产到应用的全链条体系，涵盖小分子原料药及制剂、生物大分子预防及治疗药物、体外检测试剂（IVD）全系产品，是大多数国内规模养殖企业的核心动保合作伙伴，并拓展服务网络至东南亚、中东、非洲等地区，全球化布局初具规模。依托“农业农村部兽药制剂创制重点实验室”、“天津市企业技术中心”、“动物用生化制药技术工程中心”、“天津市动物专用化学合成原料及制剂企业重点实验室”等研发平台，挑战动保2013~2023年猪用化药新药获批数量全国第一，产品开发水平稳居行业领先地位。获得“国家高新技术企业” “天津市科技小巨人领军企业”、“国家科学技术进步二等奖”等荣誉，先后入围“国际未来农业食品行业百强榜”②、“天津市民营企业100强”③、“全国化药制剂TOP15”④、“全国化药制剂企业销售前十”⑤榜单。伴随宠物经济崛起，伴侣动物业务实现快速增长。挑战动保总部基地集研发、生产、工业展示与科普教育于一体，以智能、绿色理念赋能产业升级。秉持“呵护动物健康，助力食品安全”使命，矢志成为受业界推崇的创新型动保企业，为实现民族兽药的高质量发展努力奋斗。① 数据来源：《中国兽药信息网》、《新猪派》整理② 数据来源：35斗③ 数据来源：第十二届天津民营经济健康发展工程发布会 ④数据来源：新牧网“兽药制剂TOP15企业盘点”； ⑤数据来源：兽药产业发展报告（2024年度）附录。 Tianjin Speerise Challenge Biotechnology Co., LTD. (Abbreviation:Challenge Animal Health) was established in 2002. The company focuses on animal health, food and companion animal health. Challenge Animal Health drives development with innovation, build a full-chain industrial system from drug R & D, production to application, covering small molecule raw materials and preparations, biological macromolecules for prevention and treatment, and in vitro detection (IVD) products. It is the core animal protection partner of most domestic scale breeding enterprises, and expands its service network to Southeast Asia, Middle East, Africa and other regions. The global layout has begun to take shape. Relying on provincial R & D platforms such as“ the Key Laboratory of Veterinary Drug Preparation Innovation (Ministry of Agriculture and Rural Affairs),“Tianjin City Enterprise Technology Center","Animal Biochemical Pharmaceutical Technology Engineering Center","Tianjin City Key Laboratory of Animal Chemical Synthesis Raw Materials and Preparations Enterprise," the number of approved new chemical drugs for pigs ranked first in China① from 2013 to 2023, and the product development level remained in the leading position in the industry. It won honors such as "National High-tech Enterprise"、"Tianjin City Science and Technology Little Giant Leading Enterprise" and "Second Prize of National Science and Technology Progress Award". It has been shortlisted in the list of "Top 100 International Future Agricultural Food Industry"②, "Top 100 Private Enterprises in Tianjin City"③ and "TOP 15 National Chemical Preparations"④. With the rise of pet economy, companion animal business has achieved rapid growth. The headquarters base of Challenge Animal Health to integrate R & D, production, industrial display and science popularization education, and enable industrial upgrading with intelligent and green concepts. Adhering to the mission of " Care For Animal Health and Contribute To Food Safety ", we are determined to be an innovative animal health enterprise that is respected by the industry and strive to achieve high-quality development of ethnic veterinary drugs. ① Data sources:《China Institute of Veterinary Drug Control》and 《New Pig Pie》 collation; ② Data sources:35 Dou; ③ Data sources:The Press Conference of the 12th Tianjin Private Economy Healthy Development Project; ④ Data sources:Xin Mu Net "Review of the Top 15 Veterinary Drug Formulation Companies"; ⑤Annual Report on Development of Veterinary Medicine Industry in China(2024) appendix; 公司地址：天津市西青区张家窝工业园区安泽道6号 NO.6,Anze Road,Zhangjiawo Industrial Zone,Xiqing District,Tianjin 服务热线：（86）22-87980458 公司网址：www.tjtzdb.com 电子信箱：service@tjtzdb.com 2 SECOND 产品介绍（1）挑战诺康——恩诺沙星注射液（20%） CHALLENGE NuoKang-Enrofloxacin Injection(20%) 恩诺沙星为氟喹诺酮类畜禽专用广谱杀菌药，对敏感菌有明显的抗菌后效应。本品肌内注射吸收迅速而完全，生物利用度猪为90.56％；在动物体内广泛分布，能在白细胞蓄积达血浆浓度的140倍，用于治疗猪敏感菌引起的乳房炎-子宫炎-无乳综合症（MMA）（数据来源于农业农村部标准说明书）。（2）多康——鸡传染性法氏囊病精制蛋黄抗体 Antibodies Extracted from Chinken Egg-Yolk against Infectious Bursal Disease 经广泛病料采集，分离纯化当前流行毒株，制备高免鸡蛋。经酸化萃取、高速离心、超滤等现代生产工艺，结合HOF多重灭活技术，既可提纯卵黄中的免疫球蛋白，又减少了产品污染的可能性。大量临床试验表明，效价稳定、疗效确实、保存期长、使用方便，不影响胴体品质。（3）挑战泰瑞美——泰拉霉素注射液 Tinamecin-Tulathromycin Injection 抗菌活性高，用量少（2.5mg/kg.wt），注射后药物广泛分布，17分钟药物浓度即可达到峰值；且消除缓慢，单一剂量可持续整个疗程。（4）挑战沙米——沙咪珠利溶液 CHALLENGE Saomizuril-Ethanamizuril Solution 国家一类新兽药，全新三嗪类化合物，对解决球虫耐药性难题，维护动物健康提供了有力保障。同时，其较短的休药期可减少药物残留对动物和食品安全的影响。（5）挑战优盾——盐酸聚六亚甲基双胍溶液 Poly (hexamethylenebiguanide)hydrochloride Solution 盐酸聚六亚甲基双胍溶液的核心有效成分为聚六亚甲基双胍盐酸盐（PHMB），是一种细胞膜活性抗菌剂，结构中的甲基胍基团使聚合物呈正电性，与菌体表面负电荷的各类细菌、病毒吸附，从而抑制分裂，使其丧失活性。该消毒剂对细菌繁殖体有很好的杀灭作用，对真菌和分歧杆菌以及某些亲水性病毒有很好的杀灭效果。（6）媒可约——烯丙孕素内服溶液 Altrenogest-Altrenogest Oral Solution 用于批次生产过程中，既可优化养猪管理，同步母猪发情，实现全进全出，又能够有效阻断疾病的水平传播。（7）复倍喜——盐酸溴己新可溶性粉 Furbromxine-Bromhexine Hydrochloride Soluble Powder 具有祛痰解表、有效防治动物呼吸道疾病的功效。在兽医临床中，可单独用于黏液堵塞呼吸道为主要特征的呼吸道疾病的治疗；也可与多种抗生素联合应用，起到协同增效的作用，休药期0天（数据来源于农业农村部标准说明书）。（8）梦不同——孟布酮注射液/粉 Menbutong-Menbutone Injection/Powder 具有刺激胃肠消化液分泌的作用，适用于猪、马、牛、绵羊、山羊和犬多种动物。其中对于仔猪消化不良，母猪消化不良、食欲减退、便秘腹胀等胃肠机能障碍疾病作用十分明显，也可预防产褥热引起的消化不良，辅助治疗肠炎、中毒性肝功能受损、肝营养不良以及肝退行性疾患（如脂肪肝），既可单独使用，也可作为辅助治疗用药或与其他药物联合用药。（9）挑战康壮——复方布他磷注射液 Compound Butaphosphan Injection 专为动物设计的矿质元素补充剂，主要成分为布他磷与维生素B12，可通过静脉/肌注的方式为动物提供必要的营养补充，促进动物机体快速恢复到正常状态。（10）禽腺病毒（I群4型）卵黄抗体 Fowl Adenovirues（Group I Serotype 4）Extracted Egg-yolk Antibodies 用于预防禽腺病毒（I群4型）引起的疾病。产品中和抗体效价不低于1∶256，接种后的保护期为168h，具有抗体效价高、特异性强等特点，能够快速为鸡体提供被动免疫保护。（11）普瑞巴林内服溶液 Pregabalin Oral Solution 普瑞巴林内服溶液‌是一种用于缓解猫因运输或就诊等产生应激反应的兽用处方药，主要成分为普瑞巴林，通过作用于中枢神经系统电压门控钙通道的α2δ蛋白亚基，减少神经递质过度释放，从而发挥抗焦虑和抗应激作用。该产品为5%规格的口服溶液，猫咪接受度高。（12）头孢维星钠注射液 Cefovecin Sodium for Injection 头孢维星钠在犬和猫皮下注射给药后吸收迅速而完全，蛋白结合率高，分别达到98.5%和99.8%。按照8mg/kg体重剂量给犬和猫进行单次皮下注射后，主要药代动力学参数分别为：峰浓度（Cmax）121µg/mL、141µg/mL；达峰时间（tmax）6.2h、2.0h；半衰期（t1/2）133h 和166h。（13）口蹄疫病毒SAT-1型RT-PCR试剂盒 RT-PCR Kit for SAT-1 Serotype of Foot-and-Mouth Disease Virus 基于探针法实时荧光逆转录PCR（qRT-PCR）技术开发的核酸检测产品，用于定性检测水疱皮/液、OP液、血清、组织等样本中的SAT-1型口蹄疫病毒 RNA，可用于偶蹄动物SAT-1型口蹄疫的快速确诊与鉴别诊断、疫情早期筛查及隐性感染监测与流行病学调查、口岸/调运检疫、养殖场常态化防控与净化评估等。（14）禽白血病病毒P27抗原检测试剂盒 Avian Leukosis Virus Antigen Detection Kits 针对传统禽白血病检测试剂盒灵敏度不足、变异毒株漏检率高、多亚型覆盖能力弱等行业痛点，创新采用“高亲和力重组兔单抗+多包被捕获协同夹心”核心技术将抗原最低检出限从5ng/mL降至0.5ng/mL，对ALV-K等重组毒株识别能力大幅提升。（15）整肠泰——混合型饲料添加剂固体果寡糖 Ⅳ RT-PCR Kit for SAT-1 Serotype of Foot-and-Mouth Disease Virus 原料组成果寡糖，产品成分分析保证值果寡糖 10%；水分≤10%。群体给药：禽每袋500g兑水1000～2000L，猪每袋500g拌料500～1000kg，反刍动物每袋500g拌料500～1000kg，貂、狐、貉每袋500g拌料1000kg，水产动物每袋500g拌料500～1000kg，均可长期使用。个体给药：貂、狐、貉：每天每只0.1g，猪每10kg体重0.5～1g，可长期使用；（16）益生菌粉（犬猫通用） Probiotic Powder 1900亿 cfu/kg高含量不虚标。嗜酸乳杆菌抑制肠道有害菌生长，调节肠道菌群平衡；酿酒酵母+维生素B群+维生素E，营养全面升级；益生菌+益生元，“双重养护”；羊乳粉+鸡肝粉，提高适口性，主动吃、不抗拒；添加3种消化酶，促进营养吸收（蛋白酶、脂肪酶、木瓜蛋白酶）（17）益生菌片（猫专用、犬专用） Probiotic Tablet 1900亿 cfu/kg 高含量不虚标。五菌联株，全面覆盖肠道需求；酿酒酵母+维生素B群，双重营养支持；益生菌+益生元，“双重养护”；鸡肝粉+蛋黄粉，提高适口性，主动吃、不抗拒；片剂设计，喂食更方便。（18）鲨鱼软骨素片（犬猫通用） Shark Cartilage Tablets 赛犬同款，高含量双核心关节营养，萄糖胺+鲨鱼软骨素，构建关节养护基础；六重关节养护矩阵不止软骨素，更是全链路关节营养方案（葡萄糖胺、硫酸软骨素、绿唇贻贝、透明质酸钠、胶原蛋白、维生素D3+钙）（19）南极磷虾鱼油（犬猫通用） Antarctic Krill & Fish Oil 南极磷虾油+鱼油双源配方，营养更丰富；DHA+EPA总含量≥250000mg/kg，高含量补充；天然维生素E抗氧化，产品稳定性更好；液体泵头设计，定量方便，拌粮简单；DHA添加，日常脑眼营养补充；磷虾油天然鲜香，适口性好。（20）营养化毛膏 Hairball Paste 科学温和化毛，减少毛球堆积（麦芽糖+膳食纤维+圆苞车前子壳组合）；牛磺酸添加，边化毛边补充营养，维持心脏，视力健康；添加鱼油，呵护毛发健康亮泽；羊乳粉添加，适口性更好；多重维生素营养配方（维生素A，D3，E，B族维生素），全面呵护成长；多种矿物质添加（锌，铁，铜，锰），全面补充成长所需营养。欢迎加入展商行列拓展全球畜牧市场共觅新商机 VIV Select China 2026 免费参观登记即获展商名单长按识别二维码或点击此处（可中英文切换） 2026.移师上海 VIV SELECT CHINA 2026 亚洲国际集约化畜牧展览会（上海） >> 8月19-21日丨上海世博展览馆 International Trade show from Feed to Food 链接全球共筑一站式畜牧商贸平台 Booth Booking·参展咨询 VIV SELECT CHINA 2027亚洲国际集约化畜牧展览会（上海） ////////// 马野（Mr. Aason Ma） aason.ma@globusevents.com 021-6195 3565 +86-137 6165 9090 陈晓婷（Ms. Vicky Chen） vicky.chen@globusevents.com 021-61953541 +86-138 1629 2150 虞鸥平（Mr. Matthew Yu） matthew.yu@globusevents.com 021-6195 3536 +86- 158 0083 0669 Mr.Philippe Verstuyft (based in Europe ）海外销售 philippe@vnueurope.com +31 6 1517 3564 Mr.Umberto Cioffi (based in Europe ）海外销售 umberto@vnueurope.com +31 6 1188 8084 ////////// 张娅坪（Ms. Gemma Zhang）市场宣传/会议合作 gemma.zhang@globusevents.com 021-61956095 +86- 136 6153 9222 胡颖（Ms. Carolyn Hu ）市场宣传/会议合作 carolyn.hu@globusevents.com 021-61953516 +86- 159 2146 1780 白雪（Ms. Snow Bai）市场宣传/会议合作 snow.bai@globusevents.com 021-61953554 +86- 139 1737 2737 郝永丽（Ms. Well Hao）商务合作 well.hao@globusevents.com 021-6195 6015 +86- 135 2468 9191 International Trade Show From Feed to Food 链接全球共筑一站式畜牧商贸平台 WWW.VIVWORLDWIDE.CN

2026-07-17

·挑战动保

相约VIV SELECT CHINA 2026，见证挑战动保的“全”与“新”

2026年亚洲国际集约化畜牧展览会（VIV Select China 2026），将于2026年8月19日-21日在上海世博展览馆盛大举办。挑战动保将在H2展馆D2311展位，携子公司标允生物、默易捷倾力打造涵盖动保精品、诊断试剂盒、动物营养、功能性添加剂及预混料、宠物保健等全系产品展示区。历经多年发展，挑战动保已实现多剂型全覆盖，灵活满足不同养殖场景的用药需求。同时，挑战动保研究院持续推动产品工艺优化与品质升级，在适口性、稳定性、生物利用度等核心指标上不断突破，形成良性迭代的产品梯队；标允生物持续深耕诊断试剂盒系列产品；默易捷则在宠物保健产品、动物营养、功能性添加剂及预混料领域不断突破。挑战动保携子公司同时发力，致力于以更完整的产品生态，赋能行业发展。在此，我们诚挚恭候业界同仁莅临H2展馆D2311展位，交流探讨，共话发展。 01 展位效果图 /// 展区平面图 02 科研为基成果为证挑战动保，因研发创新而立足，因持续深耕而致远。公司先后获得国家科学技术进步二等奖、北京市科学技术进步一等奖、天津市科学技术进步二等奖，并被认定为农业农村部兽药制剂创制重点实验室。每一项认可，都是对我们在研发创新和品质把控上长期坚守的价值印证。本届展会，我们精选多款代表性产品同台展出，旨在以系统化的产品组合方案，切实回应养殖一线对安全高效与提效降本的现实期待。 01 动保精品与产品方案 Challenge Animal Health — Key Premium Products B级猪苗健康管理方案挑战沙米——沙咪珠利溶液国家一类新兽药，全新三嗪类化合物，对解决球虫耐药性难题，维护动物健康提供了有力保障。同时，其较短的休药期可减少药物残留对动物和食品安全的影响。 A National Class I new veterinary drug, this is a novel triazine compound that provides a robust solution to the challenge of coccidial drug resistance, safeguarding animal health. Its relatively short withdrawal period minimizes the impact of drug residues on animal health and food safety. 挑战泰瑞美——泰拉霉素注射液抗菌活性高，用量少（2.5mg/kg.wt），注射后药物广泛分布，17分钟药物浓度即可达到峰值；且消除缓慢，单一剂量可持续整个疗程。 It exhibits high antibacterial activity and requires a low dosage (2.5 mg/kg body weight). Following injection, the drug is widely distributed, reaching peak plasma concentrations within 17 minutes. Elimination is slow, and a single dose provides coverage for the entire treatment course. 挑战诺康——恩诺沙星注射液（20%）恩诺沙星为氟喹诺酮类畜禽专用广谱杀菌药，对敏感菌有明显的抗菌后效应。本品肌内注射吸收迅速而完全，生物利用度猪为90.56％；在动物体内广泛分布，能在白细胞蓄积达血浆浓度的140倍，用于治疗猪敏感菌引起的乳房炎-子宫炎-无乳综合症（MMA）（数据来源于农业农村部标准说明书）。 Enrofloxacin is a fluoroquinolone broad-spectrum antibacterial agent specifically for livestock and poultry, with a significant post-antibiotic effect against susceptible bacteria. Following intramuscular injection, it is rapidly and completely absorbed, with a bioavailability of 90.56% in pigs. It is widely distributed in animal bodies and can accumulate in leukocytes at concentrations up to 140 times that in plasma. It is indicated for the treatment of mastitis-metritis-agalactia syndrome (MMA) caused by susceptible bacteria in pigs (data sourced from the standard package insert of the Ministry of Agriculture and Rural Affairs). 多康——鸡传染性法氏囊病精制蛋黄抗体经广泛病料采集，分离纯化当前流行毒株，制备高免鸡蛋。经酸化萃取、高速离心、超滤等现代生产工艺，结合HOF多重灭活技术，既可提纯卵黄中的免疫球蛋白，又减少了产品污染的可能性。大量临床试验表明，效价稳定、疗效确实、保存期长、使用方便，不影响胴体品质。 Through extensive field sample collection, isolation, and purification of currently circulating virus strains, hyperimmune eggs are produced. Modern production processes including acid extraction, high-speed centrifugation, ultrafiltration, combined with HOF multi-step inactivation technology, enable both the purification of immunoglobulins from egg yolk and a reduction in the risk of product contamination. Extensive clinical trials have demonstrated stable potency, reliable efficacy, long shelf life, ease of use, and no adverse effects on carcass quality. 挑战优盾——盐酸聚六亚甲基双胍溶液盐酸聚六亚甲基双胍溶液的核心有效成分为聚六亚甲基双胍盐酸盐（PHMB），是一种细胞膜活性抗菌剂，结构中的甲基胍基团使聚合物呈正电性，与菌体表面负电荷的各类细菌、病毒吸附，从而抑制分裂，使其丧失活性。该消毒剂对细菌繁殖体有很好的杀灭作用，对真菌和分歧杆菌以及某些亲水性病毒有很好的杀灭效果。 Polyhexamethylene Biguanide Hydrochloride Solution，The core active ingredient of this solution is polyhexamethylene biguanide hydrochloride (PHMB), a cell membrane-active antimicrobial agent. The methyl biguanide groups in its structure impart a positive charge to the polymer, allowing it to adsorb onto the negatively charged surfaces of various bacteria and viruses. This adsorption inhibits cell division and inactivates the microorganisms. This disinfectant exhibits excellent killing activity against bacterial vegetative cells, and is also highly effective against fungi, mycobacteria, and certain hydrophilic viruses.The core active ingredient of this solution is polyhexamethylene biguanide hydrochloride (PHMB), a cell membrane-active antimicrobial agent. The methyl biguanide groups in its structure impart a positive charge to the polymer, allowing it to adsorb onto the negatively charged surfaces of various bacteria and viruses. This adsorption inhibits cell division and inactivates the microorganisms. This disinfectant exhibits excellent killing activity against bacterial vegetative cells, and is also highly effective against fungi, mycobacteria, and certain hydrophilic viruses. 媒可约——烯丙孕素内服溶液用于批次生产过程中，既可优化养猪管理，同步母猪发情，实现全进全出，又能够有效阻断疾病的水平传播。 Used in batch farrowing production systems, it optimizes swine management by synchronizing estrus in sows, enabling all-in/all-out production, and effectively interrupting the horizontal transmission of diseases. 复倍喜——盐酸溴己新可溶性粉具有祛痰解表、有效防治动物呼吸道疾病的功效。在兽医临床中，可单独用于黏液堵塞呼吸道为主要特征的呼吸道疾病的治疗；也可与多种抗生素联合应用，起到协同增效的作用，休药期0天（数据来源于农业农村部标准说明书）。 It has expectorant and antipyretic properties and is effective in preventing and treating respiratory diseases in animals. In veterinary practice, it can be used alone for respiratory diseases characterized primarily by mucus obstruction of the airways, or in combination with various antibiotics for synergistic effects. The withdrawal period is 0 days(data sourced from the standard package insert of the Ministry of Agriculture and Rural Affairs). 普瑞巴林内服溶液普瑞巴林内服溶液‌是一种用于缓解猫因运输或就诊等产生应激反应的兽用处方药，主要成分为普瑞巴林，通过作用于中枢神经系统电压门控钙通道的α2δ蛋白亚基，减少神经递质过度释放，从而发挥抗焦虑和抗应激作用。该产品为5%规格的口服溶液，猫咪接受度高。 Pregabalin Oral Solution is a veterinary prescription drug for alleviating stress responses in cats induced by transport or veterinary visits. Its main ingredient, pregabalin, exerts anxiolytic and anti-stress effects by binding to the α2δ protein subunit of voltage-gated calcium channels in the central nervous system, thereby reducing excessive neurotransmitter release. This product is a 5% oral solution that is well accepted by cats. 头孢维星钠注射液头孢维星钠在犬和猫皮下注射给药后吸收迅速而完全，蛋白结合率高，分别达到98.5%和99.8%。按照8mg/kg体重剂量给犬和猫进行单次皮下注射后，主要药代动力学参数分别为：峰浓度（Cmax）121µg/mL、141µg/mL；达峰时间（tmax）6.2h、2.0h；半衰期（t1/2）133h 和166h。 Following subcutaneous administration in dogs and cats, cefovecin sodium is rapidly and completely absorbed, with high protein binding rates of 98.5% and 99.8%, respectively. After a single subcutaneous injection at a dosage of 8 mg/kg body weight in dogs and cats, the major pharmacokinetic parameters are as follows: peak plasma concentration (Cmax) 121 µg/mL and 141 µg/mL; time to peak concentration (tmax)6.2 h and 2.0 h; and elimination half-life(t1/2)133 h and 166 h, respectively. 02 标允生物诊断试剂盒产品 Biaoyun — Diagnostic Kit Products 极速 pcr 产品极速 PCR 仪依托液态金属涂覆陶瓷加热、空气浴冷却实现高效温控，8 个反应孔独立控温，精准完成 PCR 所需升降温循环与恒温步骤，完成核酸扩增。设备为每孔配置独立四通道光学检测单元，实时采集荧光数据，同步监控各样本荧光变化。系统依据采集到的荧光数据自动计算 Ct 值，结合系列浓度标准品建立 Ct 值与模板初始浓度（拷贝数）对数的线性标准曲线，即可定量测算待测样本的原始核酸浓度或拷贝数。应用场景：规模化畜禽养殖场疫病防控、第三方检测实验室/科研单位、基层畜牧兽医防疫机构、屠宰加工企业畜禽产品安全检。仪器优势：独立模块化设计：各模块程序独立设置，可并行运行不同扩增方案；单一模块故障不影响其余模块正常实验。极速精准温控：双加热片同步加热，多点同步测温，升温速率最高 12.5℃/s；高速磁浮风机搭配双曲线扰流风道，定向强风高效降温。免校准稳定光路：固化一体式光路，设备移动后无需校准；四通道实时荧光检测，轻松搭建多重PCR检测体系。多样本通用适配：兼容环境样本、咽拭子、唾液、尾根血等多种检测样本，适用场景广泛。 The ultra-fast PCR instrument realizes high-efficiency temperature control via liquid metal-coated ceramic heating and air bath cooling. Its eight reaction wells feature independent temperature control, which precisely fulfills the temperature cycling and constant-temperature incubation steps required for PCR to accomplish nucleic acid amplification. Every well of the device is fitted with an independent four-channel optical detection module that acquires real-time fluorescence data and monitors fluorescence changes of all samples simultaneously. The system automatically calculates Ct valuesfrom the collected fluorescence signals. By using serially diluted standard references,alinear standard curve is generated to correlate Ct values with the logarithm of initial template concentration (copy number). This allows quantitative quantification of the original nucleic acid concentration or copy number in test specimens. Application Scenarios:Epidemic Prevention and Control for Large-Scale Livestock and Poultry Farms、Grassroots Animal Husbandry and Veterinary Epidemic Prevention Institutions、Third-Party Testing Laboratories & Scientific Research Institutions 、Safety Testing of Livestock and Poultry Products for Slaughter and Processing Enterprises。 Instrument Advantages: Independent Modular Design：Each module supports independent program configuration and can run different amplification protocols in parallel. A fault in a single module will not interfere with experiments on the rest of the modules. Ultra-Fast & Precise Temperature Control：Dual heating plates provide synchronous heating with multi-point real-time temperature monitoring, achieving a maximum ramp rate of 12.5°C/s. Fitted with high-speed maglev fans and hyperbolic turbulent air ducts, the unit generates directional high-velocity airflow for highly efficient cooling. Calibration-Free Stable Optical Path： It features an integral fixed optical structure, requiring no recalibration after equipment relocation. Four-channel real-time fluorescence detection facilitates easy construction of multiplex PCR detection systems. Compatibility with Various Sample Types： Compatible with environmental samples, throat swabs, saliva, tail-root blood and other test samples, suitable for a wide varietyof application scenarios. 禽白血病病毒P27抗原检测试剂盒针对传统禽白血病检测试剂盒灵敏度不足、变异毒株漏检率高、多亚型覆盖能力弱等行业痛点，创新采用“高亲和力重组兔单抗+多包被捕获协同夹心”核心技术将抗原最低检出限从5ng/mL降至0.5ng/mL，对ALV-K等重组毒株识别能力大幅提升。 Addressing industry pain points such as insufficient sensitivity of traditional avian leukosis detection kits, high rates of variant strain misdetection, and weak coverage of multiple subtypes, this kit innovatively employs a "high-affinity recombinant rabbit monoclonal antibody + multi-capture cooperative sandwich" core technology. This reduces the minimum detection limit for the antigen from 5 ng/mL to 0.5 ng/mL and significantly enhances the ability to detect recombinant strains such as ALV-K. 03 默易捷功能性添加剂产品 MCMS— Functional Feed Additives 04 “维谱安”宠物系列产品 "Vetpura" — Pet Care Product Series 益生菌粉（犬猫通用）嗜酸乳杆菌抑制肠道有害菌生长，调节肠道菌群平衡；酿酒酵母+维生素B群+维生素E，营养全面升级；益生菌+益生元，“双重养护”；羊乳粉+鸡肝粉，提高适口性，主动吃、不抗拒；添加3种消化酶，促进营养吸收（蛋白酶、脂肪酶、木瓜蛋白酶） Lactobacillus acidophilus inhibits the growth of harmful intestinal bacteria and regulates gut microbiota balance;Saccharomyces cerevisiae、vitamin B complex、vitamin E provide comprehensive nutritional enhancement;probiotics、prebiotics offer"dual protection";goat milk powder、chicken liver powder improve palatability, encouraging voluntary intake without resistance;supplemented with 3 digestive enzymes (protease,lipase,papain)to promote nutrient absorption. 鲨鱼软骨素片（犬猫通用）赛犬同款，高含量双核心关节营养，萄糖胺+鲨鱼软骨素，构建关节养护基础；六重关节养护矩阵，不止软骨素，更是全链路关节营养方案（葡萄糖胺、硫酸软骨素、绿唇贻贝、透明质酸钠、胶原蛋白、维生素D3+钙） The same formula used for racing dogs.High-content dual-core joint nutrition featuring glucosamine、shark cartilage builds the foundation for joint care.A six-in-one joint support matrix–more than just chondroitin,it provides a full-spectrum joint nutritional solution (glucosamine,chondroitin sulfate,green-lipped mussel,sodium hyaluronate,collagen,vitamin D₃、calcium). 南极磷虾鱼油（犬猫通用）南极磷虾油+鱼油双源配方，营养更丰富；DHA+EPA总含量≥250000mg/kg，高含量补充；天然维生素E抗氧化，产品稳定性更好；液体泵头设计，定量方便，拌粮简单；添加DHA，日常脑眼营养补充；磷虾油天然鲜香，适口性好。 A dual-source formula combining Antarctic krill oil and fish oil for richer nutrition;total DHA、EPA content≥250,000mg/kg for high-level supplementation;natural vitamin E provides antioxidant protection for better product stability;liquid pump dispenser allows for easy, accurate dosing and simple mixing with food;DHA supplementation supports daily brain and eye nutrition;natural umami flavor of krill oil ensures excellent palatability. 营养化毛膏科学温和化毛，减少毛球堆积（麦芽糖+膳食纤维+圆苞车前子壳组合）；牛磺酸添加，边化毛边补充营养，维持心脏，视力健康；添加鱼油，呵护毛发健康亮泽；羊乳粉添加，适口性更好；多重维生素营养配方（维生素A，D3，E，B族维生素），全面呵护成长；多种矿物质添加（锌，铁，铜，锰），全面补充成长所需营养。 Scientifically formulated for gentle hairball management,reducing hairball accumulation(maltose、dietary fiber、psyllium husk combination);taurine supplementation supports nutrition while managing hairballs,maintaining heart and vision health;fish oil addition promotes healthy,glossy coat;goat milk powder enhances palatability; multi-vitamin nutritional formula(vitamin A, D₃, E, and B-complex vitamins)provides comprehensive support for growth;multiple mineral supplements(zinc,iron,copper,manganese)ensure complete nutritional support for healthy development. 03 专业团队全程值守展会期间，挑战动保、标允生物、默易捷的服务团队将全程值守，以双语服务为您提供可落地的养殖方案与参考建议。 04 H2 D2311 期待遇见您挑战动保携子公司标允生物、默易捷，期待与您相聚VIV Select China Hall2 D2311，我们不见不散。 #挑战动保 #B级猪健康管理方案 #默易捷 #维谱安 #展会直击 05 挑战动保简介　　天津市中升挑战生物科技有限公司（简称：挑战动保）成立于2002年，公司专注于动物保健领域，聚焦食品及伴侣动物健康。挑战动保以创新驱动发展，构建药物研发、生产到应用的全链条体系，涵盖小分子原料药及制剂、生物大分子预防及治疗药物、体外检测试剂（IVD）全系产品，是大多数国内规模养殖企业的核心动保合作伙伴，并拓展服务网络至东南亚、中东、非洲等地区，全球化布局初具规模。　　依托“农业农村部兽药制剂创制重点实验室”、“天津市企业技术中心”、“动物用生化制药技术工程中心”、“天津市动物专用化学合成原料及制剂企业重点实验室”等研发平台，挑战动保2013~2023年猪用化药新药获批数量全国第一①，产品开发水平稳居行业领先地位。获得“国家高新技术企业” “天津市科技小巨人领军企业”、“国家科学技术进步二等奖”等荣誉，先后入围“国际未来农业食品行业百强榜”②、“天津市民营企业100强”③、“全国化药制剂TOP15”④、“全国化药制剂企业销售前十”⑤榜单。伴随宠物经济崛起，伴侣动物业务实现快速增长。　　挑战动保总部基地集研发、生产、工业展示与科普教育于一体，以智能、绿色理念赋能产业升级。秉持“呵护动物健康，助力食品安全”使命，矢志成为受业界推崇的创新型动保企业，为实现民族兽药的高质量发展努力奋斗。①数据来源：《中国兽药信息网》、《新猪派》整理②据来源：35斗③数据来源：第十二届天津民营经济健康发展工程发布会 ④数据来源：新牧网“兽药制剂TOP15企业盘点”； ⑤数据来源：兽药产业发展报告（2024年度）附录。 Tianjin Speerise Challenge Biotechnology Co., LTD.(Abbreviation:Challenge Animal Health) was established in 2002. The company focuses on animal health,food and companion animal health.Challenge Animal Health drives development with innovation,build a full-chain industrial system from drug R & D,production to application,covering small molecule raw materials and preparations,biological macromolecules for prevention and treatment,and in vitro detection(IVD)products. It is the core animal protection partner of most domestic scale breeding enterprises,and expands its service network to Southeast Asia,Middle East,Africa and other regions.The global layout has begun to take shape. Relying on provincial R & D platforms such as"the Key Laboratory of Veterinary Drug Preparation Innovation"(Ministry of Agriculture and Rural Affairs),"Tianjin City Enterprise Technology Center","Animal Biochemical Pharmaceutical Technology Engineering Center","Tianjin City Key Laboratory of Animal Chemical Synthesis Raw Materials and Preparations Enterprise,"the number of approved new chemical drugs for pigs ranked first in China①from 2013 to 2023, and the product development level remained in the leading position in the industry. It won honors such as "National High-tech Enterprise"、"Tianjin City Science and Technology Little Giant Leading Enterprise" and "Second Prize of National Science and Technology Progress Award". It has been shortlisted in the list of "Top 100 International Future Agricultural Food Industry"②,"Top 100 Private Enterprises in Tianjin City"③and "TOP 15 National Chemical Preparations"④"Top 10 National Veterinary Chemical Drug Preparation Manufacturers by Sales"⑤,With the rise of pet economy, companion animal business has achieved rapid growth. The headquarters base of Challenge Animal Health to integrate R & D, production, industrial display and science popularization education, and enable industrial upgrading with intelligent and green concepts. Adhering to the mission of " Care For Animal Health and Contribute To Food Safety ", we are determined to be an innovative animal health enterprise that is respected by the industry and strive to achieve high-quality development of ethnic veterinary drugs. ①Data sources:《China Institute of Veterinary Drug Control》and《New Pig Pie》collation; ②Data sources:35 Dou; ③Data sources:The Press Conference of the 12th Tianjin Private Economy Healthy Development Project; ④Data sources:Xin Mu Net“Review of the Top 15 Veterinary Drug Formulation Companies”; ⑤Annual Report on Development of Veterinary Medicine Industry in China(2024)appendix. 06 展会概览【展会名称】 2026年亚洲国际集约化畜牧展览会 VIV Select China 2026 【办展时间】 2026年8月19日-21日【展会地点】上海世博展览馆 06 交通小贴士【地址】上海市浦东新区国展路1099号【地铁】地铁7、8号线:“耀华路”站4号出口; 地铁13号线:“世博大道"站3、4号出口【公交】浦东南路站、上南路站(82路、83路、177路、314路、454路、576路、734路、786路、818路、974路、978路、隧道一线、万周线、周南线等) END 编辑：张静校对：张润泽审核：逯永强、韩治方

100 项与聚己缩胍相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08399	聚己缩胍	D08AC05	DB12277

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
棘阿米巴角膜炎	欧盟	SIFI SpA	2024-08-22
棘阿米巴角膜炎	冰岛	SIFI SpA	2024-08-22
棘阿米巴角膜炎	列支敦士登	SIFI SpA	2024-08-22
棘阿米巴角膜炎	挪威	SIFI SpA	2024-08-22
消毒剂	-	B. Braun Medical, Inc.	-
创伤和损伤	-	B. Braun Medical, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03274895 (Pubmed) 人工标引	临床3期	棘阿米巴角膜炎	127	PHMB 0.02%+ propamidine 0.1%	觸鹹繭鏇簾顧選簾製築(壓顧鏇鹽蓋餘淵簾觸壓) = 醖鏇顧積願壓築網夢糧願壓鹹淵鬱簾鹹襯餘繭 (繭築鏇願廠簾憲鬱製夢 ) 更多	积极	2024-03-01
				PHMB 0.08%+ placebo	觸鹹繭鏇簾顧選簾製築(壓顧鏇鹽蓋餘淵簾觸壓) = 範廠觸繭廠窪齋襯網網願壓鹹淵鬱簾鹹襯餘繭 (繭築鏇願廠簾憲鬱製夢 ) 更多
NCT03274895 (The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial, CTgov)	临床3期	棘阿米巴角膜炎	135	placebo+PHMB 0.08% (PHMB 0.08% Plus Placebo)	蓋夢鹹艱遞獵願壓襯膚 = 鑰夢夢築選構膚顧鑰鑰願壓廠獵蓋顧醖蓋獵齋 (餘願淵積窪鹽夢艱選鬱, 襯構鬱淵鹹醖獵範壓蓋 ~ 鹹鹹艱鹹積壓齋顧襯餘) 更多	-	2023-08-02
				Propamidine 0.1%+PHMB 0.02% (PHMB 0.02% Plus Propamidine 0.1%)	蓋夢鹹艱遞獵願壓襯膚 = 壓繭淵糧網範憲蓋簾淵願壓廠獵蓋顧醖蓋獵齋 (餘願淵積窪鹽夢艱選鬱, 鹽願醖壓餘選衊鏇淵糧 ~ 獵壓襯窪鬱壓簾膚範選) 更多
NCT03274895 (PRNewswire) 人工标引	临床3期	棘阿米巴角膜炎	135	Placebo+Polihexanide	齋蓋醖齋衊膚餘範遞襯(窪顧鑰鏇醖夢鬱繭觸壓) = 夢艱構醖積製艱餘膚鹽衊艱構衊餘積壓簾願選 (窪糧鬱範構顧築鹹願蓋 ) 更多	非劣	2022-10-13
				polihexanide+Polihexanide	齋蓋醖齋衊膚餘範遞襯(窪顧鑰鏇醖夢鬱繭觸壓) = 壓艱衊獵網鏇觸鏇夢鹹衊艱構衊餘積壓簾願選 (窪糧鬱範構顧築鹹願蓋 ) 更多
NCT04055233 (RECIPE, Pubmed \| Ann Surg)	临床3期	手术伤口感染	456	Antiseptica (0.9% saline)	積築鏇範網淵憲繭淵範(願觸顧夢築艱壓膚繭觸) = 鹹遞蓋觸糧築遞網艱蓋製膚顧糧繭願壓獵繭網 (壓醖築窪網積獵艱鹹淵 )	积极	2020-07-01
NCT02506257 (CTgov)	临床1期	棘阿米巴角膜炎	90	0.04% PHMB (0.04% PHMB)	醖鬱築觸醖鬱遞壓糧鹽 = 壓膚獵衊窪夢網醖選鏇選簾憲廠糧選選鏇鹽繭 (顧鏇齋鑰廠顧鑰餘範齋, 構製淵襯蓋憲鬱齋鑰壓 ~ 鬱網顧遞積築築簾淵築) 更多	-	2016-11-23
				0.06% PHMB (0.06% PHMB)	醖鬱築觸醖鬱遞壓糧鹽 = 觸獵糧餘鏇鑰蓋構網鹽選簾憲廠糧選選鏇鹽繭 (顧鏇齋鑰廠顧鑰餘範齋, 窪夢鬱鏇構夢範壓鏇獵 ~ 鹽餘醖獵顧鹹窪範衊艱) 更多
ODAK (ARVO2014)	N/A	棘阿米巴角膜炎	100	Polyhexamethylene biguanide (PHMB)	繭遞壓繭選繭膚窪鹹鏇(製壓構願鑰壓簾鑰襯憲) = 選艱顧窪膚願鑰選窪網選鏇糧艱願壓製鏇廠膚 (築製憲製襯構鏇鬱醖網 )	-	2014-04-01
				Combination therapy (PHMB and propamidine)	繭遞壓繭選繭膚窪鹹鏇(製壓構願鑰壓簾鑰襯憲) = 顧餘顧鑰壓餘簾廠範餘選鏇糧艱願壓製鏇廠膚 (築製憲製襯構鏇鬱醖網 )
NCT01153620 (Lavasept 2, CTgov)	临床4期	创伤和损伤	61	Lavasept 0.04% (Lavasept 0.04%)	顧積願鹹製壓鏇憲願壓(築遞鑰築艱選網鏇醖夢) = 範衊衊壓製窪顧襯壓壓糧繭壓膚繭積範觸齋網 (築糧糧齋夢築顧蓋糧鹹, 1.00) 更多	-	2011-11-29
				Ringer's Solution (Ringer's Solution)	顧積願鹹製壓鏇憲願壓(築遞鑰築艱選網鏇醖夢) = 淵築鏇夢積積繭襯鹹窪糧繭壓膚繭積範觸齋網 (築糧糧齋夢築顧蓋糧鹹, 0.85) 更多
AAO2004	N/A	-	43	Polyhexamethylene Biguanide (PHMB)	窪簾膚齋衊積願鏇憲齋(齋廠鹽醖繭齋窪膚夢齋) = 鬱遞艱鏇鑰膚艱獵鹹觸獵願壓艱窪選顧鹽網構 (鬱淵窪衊襯顧製積繭壓 ) 更多	不佳	2004-10-25
				Chlorhexidine (CH)	窪簾膚齋衊積願鏇憲齋(齋廠鹽醖繭齋窪膚夢齋) = 憲觸襯顧餘獵繭膚鹽願獵願壓艱窪選顧鹽網構 (鬱淵窪衊襯顧製積繭壓 ) 更多